A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.
Kaufman
H L
HL
Abert Einstein Cancer Center, Bronx, New York 10461, USA. kaufman@aecom.yu.edu
DeRaffele
G
G
Divito
J
J
Hörig
H
H
Lee
D
D
Panicali
D
D
Voulo
M
M
D000293:Adolescent; D000328:Adult; D019496:Cancer Vaccines; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D007258:Informed Consent; D015552:Injections, Intralesional / Q000379:methods; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000628:therapy*; D013223:Statistics as Topic; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; C439566:rV-Tricom